Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in over 130 patients. AVR’s PARADIGM pivotal trial is the central catalyst. This ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--egnite, Inc., a leading cardiovascular digital health company, today announced the results of its seminal research on the real-world impact of clinical ...
BRISBANE, Australia & MINNEAPOLIS--(BUSINESS WIRE)--Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of biomimetic heart ...
Individual psychosocial risk factors impact short-term outcomes after AVR—either TAVI or SAVR, according to a new study. The findings suggest that in some patients, TAVI may set them up for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results